Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CL-IO

Financiado

Cerrado

Commercial feasibility of non pathogenic Clostridium Mediated Cancer Immunothera...

Commercial feasibility of non pathogenic Clostridium Mediated Cancer Immunotherapy leveraging the presence of tumour hypoxia necrosis Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of... ver más

31/03/2020

UNIVERSITEIT MAAST...

151K€

Presupuesto del proyecto: 151K€

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

ERC-2018-PoC: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 7 años

0% 99% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITEIT MAASTRICHT

150.00K€ | Lider

ELYTT ENERGY

315.73K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2018-09-17
Fecha Fin: 2020-03-31

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 151K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immunotherapeutic strategies are powerful weapons in combating malignancies. However, only a minority of patients benefit from this therapeutic modality, as tumours develop mechanisms of immune escape and suppression and uptake of (antibody-based) agents in tumors is limited. The urgency of investigating novel strategic approaches is dictated by the high incidence and mortality rates of cancer worldwide. Lung cancer, in particular, is the leading cancer with respect to incidence and mortality (14% of new cancers). In the ERC Advanced HYPOXIMMUNO, Prof. Lambin and his team have investigated the trimodal therapy involving high precision Stereotactic Radiotherapy, hypoxia/necrosis targeting and tumour specific immunotherapy (immunocytokine L19-IL2 to push the accelerator with a checkpoint inhibitor to release the break). Despite promising results, the delivery of immunotherapeutics to the tumour site has proven to be challenging. Prof. Lambin and his team have sought to overcome this limitation with the inclusion of genetically-modified Clostridium bacteria as optimal delivery system capable of effectively delivering immunotherapeutics within the tumour. These Clostridium-bacteria selectively colonise the hypoxic/necrotic regions present in solid tumours and act as cellular factories capable of continuously producing tumour-specific immunotherapies within the tumour (watch https://vimeo.com/251022032 ). In this ERC PoC project, a team of technological and commercial experts will investigate the commercial feasibility of this innovative approach. We will prepare the first steps towards the start-up of a spin-off, by defining the exact business strategy, model and positioning for commercial success. We will develop the business strategy based on the technological aspects, the market needs and trends, and the IP-position. During CL-IO, we will gain technical and commercial proof-of-concept, providing the necessary information for potential commercialisation routes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores